Fidelity Investments’s Lifecore Biomedical LFCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$10.7K Sell
1,622
-8,479
-84% -$39.3K ﹤0.01% 4924
2026
Q2
$53K Buy
10,101
+7,880
+355% +$39.7K ﹤0.01% 4281
2026
Q1
$8.26K Sell
2,221
-1,012
-31% -$6.99K ﹤0.01% 4811
2025
Q4
$26.4K Buy
3,233
+422
+15% +$3.12K ﹤0.01% 4357
2025
Q3
$20.7K Sell
2,811
-328
-10% -$2.48K ﹤0.01% 4345
2025
Q2
$25.5K Buy
3,139
+722
+30% +$4.87K ﹤0.01% 4196
2025
Q1
$17K Buy
2,417
+388
+19% +$2.41K ﹤0.01% 4293
2024
Q4
$15.1K Buy
2,029
+504
+33% +$3.22K ﹤0.01% 4302
2024
Q3
$7.52K Buy
1,525
+105
+7% +$549 ﹤0.01% 4519
2024
Q2
$7.28K Sell
1,420
-70
-5% -$415 ﹤0.01% 4435
2024
Q1
$7.91K Sell
1,490
-3,615
-71% -$25.9K ﹤0.01% 4354
2023
Q4
$31.6K Buy
5,105
+3,209
+169% +$22.3K ﹤0.01% 3729
2023
Q3
$14.3K Sell
1,896
-297
-14% -$2.72K ﹤0.01% 3971
2023
Q2
$21.2K Buy
2,193
+166
+8% +$1.01K ﹤0.01% 3829
2023
Q1
$7.65K Buy
2,027
+1,921
+1,812% +$10.7K ﹤0.01% 4234
2022
Q4
$687 Sell
106
-333
-76% -$2.74K ﹤0.01% 4708
2022
Q3
$3.9K Sell
439
-856
-66% -$8.7K ﹤0.01% 4400
2022
Q2
$12.9K Buy
1,295
+36
+3% +$356 ﹤0.01% 4031
2022
Q1
$14.6K Buy
+1,259
New +$14K ﹤0.01% 4123
2013
Q4
– Sell
-632,536
Closed -$7.72M – 2659
2013
Q3
$7.72M Sell
632,536
-1,128,854
-64% -$15.8M ﹤0.01% 2034
2013
Q2
$23.3M Buy
+1,761,390
New +$24.4M ﹤0.01% 1595

Other funds holding LFCR

Fidelity Investments's LFCR Position: Q3 2026 in Review

Fidelity Investments reduced its Lifecore Biomedical (LFCR) stake by 84% in Q3 2026, selling an estimated $39.3K and leaving 1,622 shares worth $10.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4924.

Fidelity Investments first reported a position in LFCR in Q2 2013 and has held it in 21 quarters since. The position peaked at $23.3M in Q2 2013. 105 funds tracked by Wall St. Rank hold LFCR as of Q3 2026.

  • Fidelity Investments held 1,622 shares of Lifecore Biomedical worth $10.7K as of Q3 2026.
  • Fidelity Investments sold 8,479 Lifecore Biomedical shares in Q3 2026, an estimated $39.3K.
  • Lifecore Biomedical made up ﹤0.01% of Fidelity Investments's portfolio in Q3 2026, its #4924 holding.
  • Fidelity Investments first reported a position in Lifecore Biomedical in Q2 2013 and has held it in 21 quarters since.
  • Fidelity Investments's Lifecore Biomedical position peaked at $23.3M in Q2 2013.
  • 105 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q3 2026.

Based on Fidelity Investments's 13F filing for Q3 2026, filed 10 Nov 2026.